Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity
Citations Over TimeTop 10% of 2010 papers
Abstract
A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivatives within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK). These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines. The lead inhibitor 15, which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-positive ALCL cells. Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-positive ALCL tumor xenografts in Scid mice.
Related Papers
- → Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib(2019)15 cited
- → From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)(2017)10 cited
- → Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma(2019)7 cited
- → Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative(2009)8 cited
- Alk- Negative, Anaplastic Large Cell Lymphoma- A Case Report(2015)